Signal Clearmind's MEAI candidate is named in US veterans legislation and enters Yale and Johns Hopkins trials
Summary
The Initiative reports that Clearmind Medicine's non-hallucinogenic candidate MEAI for alcohol use disorder was named in bipartisan federal veterans legislation, and that FDA-approved trials at Yale School of Medicine and Johns Hopkins School of Medicine have begun reporting positive results.
Classification
Main topicBio & Health Tech
Region menusNorth America
Occurrencescope:country · geo_region:north_america · country:US
Impactscope:country · geo_region:north_america · country:US
Time horizon0-3 years (2026-07-26)
Last updated2026-07-29 04:49:53
Evidence 2
- Initiative Trends 2026: Collective Intelligence and Foresight from Global Wellness Leaders Global Wellness Institute page=83;section=Psychedelics and Healing Initiative Trends / TREND 2: Neuroplastogens - The Quiet Redefinition of Psychedelic Medicine 2026-05 accessed 2026-07-26
- Initiative Trends 2026: Collective Intelligence and Foresight from Global Wellness Leaders Global Wellness Institute page=84;section=Psychedelics and Healing Initiative Trends / TREND 2: Neuroplastogens - The Quiet Redefinition of Psychedelic Medicine 2026-05 accessed 2026-07-26
Part of trends 1
Directly linked issues 0
No objects.
Relation types: supports
Public id: fm-a7d811d1226c